FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Partners with Sara’s Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue
December 01, 2020 12:05 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Dec. 01, 2020 (GLOBE NEWSWIRE) --  Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced it...
FINAL Rafafel_Pharma_PHP_LOGO_Updated 05042020_V3 (1).png
Rafael Pharmaceuticals Achieves Target Enrollment of 500 Patients in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613 ®️ (devimistat) for Patients with Metastatic Pancreatic Cancer
August 06, 2020 09:00 ET | Rafael Pharmaceuticals, Inc.
CRANBURY, N.J., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today...